| Identification | Back Directory | [Name]
Benzo[cd]-1,3-benzodioxolo[5,4-f]indol-9(10H)-one, 10-[2-(dimethylamino)ethyl]-6,7-dimethoxy- | [CAS]
1170694-29-7 | [Synonyms]
RJ-34
Benzo[cd]-1,3-benzodioxolo[5,4-f]indol-9(10H)-one, 10-[2-(dimethylamino)ethyl]-6,7-dimethoxy- | [Molecular Formula]
C22H22N2O5 | [MOL File]
1170694-29-7.mol | [Molecular Weight]
394.42 |
| Hazard Information | Back Directory | [Uses]
RJ-34, an aristolactam analogue, exhibits potent antitumor activities against a broad array of cancer cell lines with GI50 values in the subnanomolar range (GI50 <0.1 nM for A431, MES-SA, MES-SA/DX5, HCT-15, and HCT-15/CLO2 cells)[1]. | [References]
[1] Nafie MS, et al. Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer. Bioorg Chem. 2022;122:105708. DOI:10.1016/j.bioorg.2022.105708 |
|
|